Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Enterprise Value (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Enterprise Value for 16 consecutive years, with -$922.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 67.89% year-over-year to -$922.4 million, compared with a TTM value of -$922.4 million through Dec 2025, down 67.89%, and an annual FY2025 reading of -$882.0 million, down 30.6% over the prior year.
  • Enterprise Value was -$922.4 million for Q4 2025 at Arrowhead Pharmaceuticals, down from -$882.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$66.3 million in Q2 2021 and bottomed at -$1.1 billion in Q1 2025.
  • Average Enterprise Value over 5 years is -$458.0 million, with a median of -$431.4 million recorded in 2023.
  • The sharpest move saw Enterprise Value soared 73.54% in 2021, then crashed 264.71% in 2023.
  • Year by year, Enterprise Value stood at -$151.8 million in 2021, then plummeted by 217.93% to -$482.5 million in 2022, then skyrocketed by 57.1% to -$207.0 million in 2023, then tumbled by 165.4% to -$549.4 million in 2024, then crashed by 67.89% to -$922.4 million in 2025.
  • Business Quant data shows Enterprise Value for ARWR at -$922.4 million in Q4 2025, -$882.0 million in Q3 2025, and -$902.9 million in Q2 2025.